-
Mashup Score: 32
Efsitora showed non-inferior HbA1c reductions and similar rates of combined clinically significant or severe hypoglycaemia versus glargine U100 in participants with type 2 diabetes treated with basal and prandial insulin. These findings show that efsitora is a well tolerated and efficacious once-weekly alternative to daily basal insulin, with a reduced injection frequency, for the treatment of adults with type 2 diabetes.
Source: www.thelancet.comCategories: General Medicine NewsTweet
-
Mashup Score: 33
Efsitora showed non-inferior HbA1c reductions and similar rates of combined clinically significant or severe hypoglycaemia versus glargine U100 in participants with type 2 diabetes treated with basal and prandial insulin. These findings show that efsitora is a well tolerated and efficacious once-weekly alternative to daily basal insulin, with a reduced injection frequency, for the treatment of adults with type 2 diabetes.
Source: www.thelancet.comCategories: General Medicine NewsTweet-
đź“Ś At #ADA2025 Once-weekly insulin efsitora alfa versus once-daily insulin glargine in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a randomised clinical trial https://t.co/8E7TRb8K8A @AmDiabetesAssn
-
-
Mashup Score: 4
Semaglutide 7.2 mg shows promising results, achieving a mean 21% weight loss in obesity treatment.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
Semaglutide 7.2 mg achieved a mean weight loss of 21% in the STEP UP trial, surpassing semaglutide 2.4 mg and placebo. Read more from #ADA2025: https://t.co/HPVudoXvIZ
-
-
Mashup Score: 2
New ADA guidelines enhance obesity care, focusing on personalized treatment, bias reduction, and inclusive practices to improve patient outcomes.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
An #ADA2025 symposium focused on new guidelines aiming to improve personalized, equitable care for obesity, and to focus on complications and risk reduction over weight loss alone. Learn more: https://t.co/TESjd1teVT
-
-
Mashup Score: 3
Automated insulin delivery systems enhance blood glucose control for pregnant women with type 1 diabetes, potentially advancing diabetes care.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
Watch Denice Feig, MD, MSc, @UofT_DoM and Lois Donovan, MD, how T1D care for pregnant women continues to evolve, including the CONCEPTT trial and pioneering CGM during pregnancy. #ADA2025 https://t.co/pMudV0M5QF
-
-
Mashup Score: 118
In adults with obesity or overweight without diabetes (type 1 or 2), individuals administered ecnoglutide had superior and sustained reduction in bodyweight versus placebo with a favourable safety profile, supporting its potential use for weight management.
Source: www.thelancet.comCategories: General Medicine NewsTweet-
📌 At #ADA2025 Ecnoglutide, a new medication for weight management, is a safe and effective, trial confirms. Read in @TheLancetEndo 👉 https://t.co/vDCXDdMxDZ @AmDiabetesAssn
-
-
Mashup Score: 10
As is now well known, obesity and excess adiposity is a global health issue, burdening people with multiple comorbidities such as type 2 diabetes, cardiovascular disease, musculoskeletal diseases, cancer, and sleep apnoea.1 The treatment of obesity and its comorbidities has been revolutionised in the past 5–10 years with the introduction of GLP-1 receptor monoagonists such as semaglutide and, more recently, the GLP-1 and glucose-dependent insulinotropic peptide receptor multiagonist tirzepatide.
Source: www.thelancet.comCategories: General Medicine NewsTweet-
@AmDiabetesAssn Comment: “GLP-1 and amylin receptor multiagonism with amycretin for obesity management” 🔗 https://t.co/pYFA7LthWr #ADA2025 @AmDiabetesAssn
-
-
Mashup Score: 12
In people with overweight or obesity, amycretin appeared safe and tolerable. Results from this first-in-human, phase 1 study support further investigation of the weight loss properties of amycretin.
Source: www.thelancet.comCategories: General Medicine NewsTweet-
@AmDiabetesAssn “Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, randomised, placebo-controlled study” 🔗 https://t.co/iVjuGlYYw6 #ADA2025 @AmDiabetesAssn
-
-
Mashup Score: 17
In people with overweight or obesity, once-weekly subcutaneous amycretin up to 60 mg had a safety and tolerability profile consistent with GLP-1 and amylin agonists. Although a high frequency of gastrointestinal events was reported, rates were similar to those seen in early-phase studies of these molecules. These results support further investigation into the weight loss properties of amycretin.
Source: www.thelancet.comCategories: General Medicine NewsTweet-
“Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: Results of a randomised, controlled, phase 1b/2a study” 🔗 https://t.co/kHePt6yezD #ADA2025 @AmDiabetesAssn
-
-
Mashup Score: 2
New ADA guidelines enhance obesity care, focusing on personalized treatment, bias reduction, and inclusive practices to improve patient outcomes.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
The @AmDiabetesAssn’s 2025 guidelines aim to improve personalized, equitable care for obesity, focusing on complications and risk reduction over weight loss alone. Read more from #ADA2025: https://t.co/JwJVzmPCxK
-
đź“Ś At #ADA2025 Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3 randomised non-inferiority trial https://t.co/Xkt6t7v0tR @AmDiabetesAssn